A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Tongji Hospital
Tongji Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sun Yat-sen University
Tongji Hospital
Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University
RenJi Hospital
Second Affiliated Hospital of Guangzhou Medical University
Tianjin Medical University Cancer Institute and Hospital
Fudan University
Sir Salimullah Medical College Mitford Hospital
RenJi Hospital
Institute of Liver and Biliary Sciences, India
Sun Yat-sen University
Second Affiliated Hospital, School of Medicine, Zhejiang University
RenJi Hospital